



August 3, 2009

BY ELECTRONIC FILING

Marlene H. Dortch
Secretary
Federal Communications Commission
445 12th Street, SW
Washington, D.C. 20554

Re: Amendment of Parts 2 and 95 of the Commission's Rules to Provide Additional Spectrum for the Medical Device Radiocommunication Service in the 413-457 MHz Band (ET Dkt. No. 09-36; RM-11404)

Dear Ms. Dortch:

NeuroSystec Corporation strongly supports expeditious Commission action to encourage deployment of medical micro-power network ("MMN") devices in the 413-457 MHz band.

NeuroSystec is a pharmaceutical company developing drugs and devices to expand the therapeutic options for physicians. We are actively involved in the research and development of fully-implantable, drug delivery systems to treat tinnitus, neuroprotection, neurostimulation, and diseases and disabilities of the ear and hearing. We are keenly aware of the tremendous physical, psychological, and financial burdens imposed by these injuries and conditions. Currently, the available medical treatment options are limited, and the demand for better, more effective options continues to grow as these injuries and conditions take their toll on an increasing number of people and their families and friends.

We are aware that the Alfred Mann Foundation ("AMF") has been developing MMN devices that could be invaluable in the treatment of various neuromuscular injuries and conditions. We believe that MMN technology provides a unique wireless approach that is unlike any commercially available medical treatment option. This technology, if successfully implemented, will revolutionize the medical treatment and therapy for millions of people suffering from debilitating neuromuscular injuries and conditions.

If there is even a small chance that this groundbreaking technology can deliver on a fraction of its promises, the Commission should dedicate the resources necessary to allow the technology to realize its full potential. We urge the Commission to allocate the full amount of spectrum requested by AMF for MMN use and to adopt service and technical rules permitting MMN operation.

Sincerely yours,

A handwritten signature in blue ink that reads "Thomas J. Lobl".

Thomas J. Lobl, Ph.D.
Vice President of Research and Development and Acting CEO